AMADIX
Early cancer detection in blood, before the symptoms appear
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Approved | 2032 |
|
PLASMA microRNAS FOR THE DETECTION OF EARLY COLORECTAL CANCERPLASMA microRNAS FOR THE DETECTION OF EARLY COLORECTAL CANCER PCT/IB2012/003035 The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early Colorectal Cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia. |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Approved | 2032 |
|
https://https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2013093635&_cid=P11-KNH83D-85980-1 | Title: PLASMA microRNAS FOR THE DETECTION OF EARLY COLORECTAL CANCER Application number: PCT/IB2012/003035 Granted: Europe (validated in: Germany, France, Spain, Italy, Denmark, Greece, United Kingdom, Ireland, Luxemburg, Swedish, Switzerland, Netherlands, Portugal, Poland, Romania, Hungary, Finland, Norway, and Belgium), Australia, Japan, South Korea, Mexico, Russia. Pending: India, United States and China Life extends: Until 2032 Brief description: Improve the protection of different embodiments comprised in the above parent application. |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Approved | 2037 |
|
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2018096154&_cid=P11-KNH84Y-86793-1 | Title: VITRO METHOD FOR IDENTIFYING COLORECTAL ADENOMAS OR COLORECTAL CANCER Application number: PCT/EP2017/080560 Pending: Europe and United States Life extends: Until 2037 Brief description: The present invention can be included in the field of personalized medicine, wherein specific biomarkers are used for identifying a given disease or disorder. Specifically, some microRNAs (also named miRNAs or miR-) are used in the present invention for identifying human subjects at risk of developing colorectal cancer (CRC) and/or colorectal adenomas (CA), preferably advanced colorectal adenomas (AA). |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Pending |
|
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2020178172&_cid=P11-KNH85J-87052-1 // | Title: PROTEIN SIGNATURE FOR THE DIAGNOSIS OF COLORECTAL CANCER AND/OR PRECANCEROUS STAGE THEREO Application number: PCT/EP2020/055277 Pending: It is not yet extended into national phases. It is being examined in the international phase. Life extends: Until 2040 Brief description: The present invention refers to an in vitro method for diagnosing, identifying or screening human subjects at risk of suffering from colorectal cancer and/or advanced colorectal adenomas, departing from the concentration level of protein biomarkers isolated from minimally-invasive samples such as blood, serum or plasma. The method of the invention offers high sensitivity and specificity, which means that it is a strong and cost-effective method for the detection of both colorectal cancer and colorectal adenomas. |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Pending |
|
http://www.amadix.com | Title: PROTEIN SIGNATURE FOR THE DIAGNOSIS/PROGNOSIS OF COLORECTAL CANCER AND/OR PRE-CANCEROUS STAGE Application number: EP20382204.4 Status: This patent is going to be withdrawn soon. It has been extended together with the following patent into the PCT phase. Patenscope link: Not publish yet |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Pending |
|
http://www.amadix.com | Title: PROTEIN SIGNATURE FOR THE DIAGNOSIS/PROGNOSIS OF COLORECTAL CANCER AND/OR PRE-CANCEROUS STAGE Application number: EP20382205.1 Status: This patent is going to be withdrawn soon. It has been extended together with the following patent into the PCT phase Patenscope link: Not publish yet |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Pending |
|
http://www.amadix.com | Title: PROTEIN SIGNATURE FOR SCREENING GENERAL POPULATION FOR COLORECTAL CANCER AND/OR PRECANCEROUS STAGE THEREOF Application number: PCT/EP2021/056984 Status: This patent has been filled in March 2021. Its aim is to extend into the PCT phase both EP patents above. Currently, this patent is being examined into the international phase. Life extends: Until 2041 Brief description: The present invention refers to an in vitro method for screening general population for colorectal cancer and/or advanced colorectal adenomas, departing from the concentration level of protein biomarkers isolated from minimally-invasive samples such as blood, serum or plasma. The method of the invention offers high sensitivity and specificity, which means that it is a strong and cost-effective method for the detection of both colorectal cancer and colorectal adenomas Patenscope link: Not publish yet |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Approved | 2033 years |
|
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2013143940&_cid=P11-KNH87A-87898-1 | Title: NEW LUNG CANCER MOLECULAR MARKERS Application number: PCT/EP2013/055823 Granted: Europe (validated in: Germany, France, Spain, Italy, Denmark, Greece, Czech Republic, United Kingdom, Ireland, Luxemburg, Swedish, Switzerland, Netherlands, Portugal, Poland, Romania, Hungary, Finland, Norway, Belgium, Turkey and Iceland) and United States Life extends: 2033 Brief description: The invention provides a method of diagnosis and/or prognosis of lung cancer, the method comprising the steps of: (a) determining the level of a C4 activation fragment in a test sample, and (b) comparing the level of the test sample with the level of a C4 activation fragment detected in a control sample, wherein if the level of C4 activation fragment is higher than the level in a reference control, it is indicative that the subject suffers lung cancer or has a bad prognosis. The present invention further provides methods for determining the risk of suffering from lung cancer as well as for deciding whether to initiate a medical regimen and to determine the efficacy of said medical regimen, based on the determination of a C4 activation fragment. C4 activation fragment, used as marker, confers high sensitivity and specificity to the methods object of the invention. |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Approved | 2038 years |
|
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2017140651&_cid=P11-KNH87V-88217-1 | Title: IN VITRO METHOD FOR THE DIAGNOSIS OF LUNG CANCER Application number: PCT/EP2017/053234 Pending: Australia, Canada, China, United States and Europe (in Europe is going to be granted this year) Life extends: 2038 Brief description: The present invention is generally related to diagnostic assays. In particular, the present invention refers to the use of at least C4c fragment as diagnostic and prognostic lung cancer marker. C4c fragment can also be useful to estimate lung cancer risk and to decide whether a medical regimen has to be initiated and to determine whether the medical regimen initiated is efficient. |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Patent | Pending | 2037 years |
|
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2017186588&_cid=P11-KNH88M-88563-1 | Title: IN VITRO METHOD FOR IDENTIFYING PANCREATIC CANCER OR INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS Application number: PCT/EP2017/059498 Pending: China, United States (is going to be granted this year), Europe (is in validating phase) Life extends: Until 2037 Brief description: The present invention can be included in the field of personalized medicine, wherein specific biomarkers are used for identifying a given disease or disorder. Specifically, some microRNAs (also named miRNAs or miR-) are used in the present invention for identifying human subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN), preferably pancreatic ductal adenocarcinoma (PDAC). |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Trademark | Approved | 10 years |
|
https://www.amadix.com | COLOCEL Type: Denominative trademark. Class 5, 35 and 44 Registered number: 018304044 (20/01/2021) Granted: Europe Pending: USA, Brazil, China, Japan, Canada, United Kingdom, India |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Trademark | Approved | 10 years |
|
https://www.amadix.com | PREVECOL Type: Denominative trademark. Class 5, 35 and 44 Registered number:018304045 (20/01/2021) Granted: Europe Pending: USA, Brazil, China, Japan, Canada, United Kingdom, India |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Trademark | Approved | 10 years |
|
https://www.amadix.com | DIAGNOLUNG Type: Denominative trademark. Class 5, 35 and 44 Registered number: 3.695.398 (07/05/2018) Granted: Spain |
| IP Type | Status | Time | Countries | Link | Coverage |
|---|---|---|---|---|---|
| Trademark | Approved | 10 years |
|
https://www.amadix.com | PANCREDIX Type: Denominative trademark. Class 5, 35 and 44 Registered number: 3.695.405 (07/05/2018) Granted: Spain |
This information is confidential, do not share or copy.
You can visit their website or
Under evaluation at least till: 17th May
KEEP REVIEWING
